What it is: A synthetic peptide that mimics ghrelin and directly stimulates pituitary GH release; also known as pralmorelin and approved as a diagnostic agent in Japan.
Research suggests: Human studies confirm it produces strong GH pulses; its approval as a diagnostic tool in Japan provides pharmacokinetic and acute safety data unusual for research peptides.
Best for: Growth hormone optimization researchers
Key thing to know: More likely than newer, more selective GHRPs to raise cortisol and prolactin alongside GH; this lack of selectivity is the primary reason ipamorelin is often preferred.
What is GHRP-2?
GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide that acts as a ghrelin mimetic — it binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor ghrelin uses. Among the first and most studied GHRPs, it has been evaluated in human clinical research more extensively than most peptides in this category.
It was developed as part of research into endogenous GH axis stimulation, with the goal of increasing GH output without the complications and supra-physiological levels associated with exogenous recombinant GH. GHRP-2 is considered one of the more potent GHRPs studied, producing robust GH pulses in both healthy adults and individuals with GH deficiency or axis dysregulation.
Pralmorelin (GHRP-2) reached clinical use in Japan as a diagnostic agent for evaluating GH secretory capacity - one of the few GHRPs to achieve any regulatory approval. This gives it a more established human safety profile than most research peptides, though its use outside diagnostic testing remains off-label and unapproved in most jurisdictions.
How it works.
In research, the proposed mechanism has several parts.
Ghrelin receptor: GHRP-2 binds GHS-R1a receptors on somatotroph cells in the anterior pituitary, as well as in the hypothalamus and other brain regions. This triggers a calcium-dependent signaling cascade that releases stored GH from pituitary somatotrophs. It also suppresses somatostatin, the hypothalamic hormone that normally inhibits GH release — a dual mechanism producing especially robust GH pulses.
Distinct from GHRH: Unlike GHRH (growth hormone releasing hormone), which stimulates new GH synthesis, GHRP-2 acts primarily on stored GH and can produce GH pulses even where endogenous GHRH signaling is blunted. That makes it a useful research tool for studying GH-axis reserve and evaluating pituitary function — which is why it gained clinical use as a diagnostic agent.
Downstream effects: GHRP-2-induced GH release acts through the GH/IGF-1 axis: elevated GH triggers hepatic IGF-1 production, driving anabolic signaling in muscle, bone, and other tissues. GHRP-2 also stimulates cortisol and prolactin via corticotroph and lactotroph cells — a characteristic that distinguishes it from more selective GHRPs like ipamorelin, and a measurable cortisol elevation worth considering in research monitoring.
What the research shows.
The research evidence breaks down as follows.
Human evidence: GHRP-2 has one of the more robust human evidence bases among research peptides. Multiple controlled clinical studies show dose-dependent GH release in healthy adults, GH-deficient patients, and elderly subjects with age-related GH-axis decline. Studies have measured downstream IGF-1 elevation, body-composition changes (reduced fat mass, increased lean mass), and improved sleep quality over extended administration.
Diagnostic approval: Its approval as a diagnostic agent in Japan (under the brand name GHRP Kaken) provides a human pharmacokinetic and acute safety profile that most research peptides lack entirely. Studies have characterized its half-life, receptor binding kinetics, and acute adverse effect profile in human subjects - information that exists for very few peptides outside the pharmaceutical development pipeline.
The limitations: The limitations are that long-term efficacy and safety data for chronic research use (beyond the acute diagnostic context) remain limited. The cortisol-stimulating properties require monitoring in protocols exceeding short-term administration. Large randomized controlled trials evaluating therapeutic outcomes in body composition or recovery contexts have not been conducted.
Biomarkers to review first.
Research protocols for GHRP-2 typically reference the following biomarkers as essential baseline context. Given its effects on cortisol, GH, and broader endocrine signaling, a thorough hormonal baseline is especially important before any protocol consideration.
What it's commonly researched with.
In research literature, GHRP-2 is frequently studied alongside GHRH analogs and other GH secretagogues to amplify or extend GH pulses. The combinations below represent what researchers have studied - not recommendations for use.